相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Christian H. Geisler et al.
BLOOD (2010)
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
Caroline Bodet-Milin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.
G. A. Salles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL).
T. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC).
A. R. Mato et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
Mars B. van 't Veer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome
Maroun Karam et al.
NUCLEAR MEDICINE COMMUNICATIONS (2009)
Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD
Jatin J. Shah et al.
BLOOD (2008)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
The mysteries of mantle cell lymphoma - do PET scans provide a clue?
Brian K. Link
LEUKEMIA & LYMPHOMA (2008)
What is the role of F-18-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
Saar Gill et al.
LEUKEMIA & LYMPHOMA (2008)
Positron emission tomography in mantle cell lymphoma
Lieselot Brepoels et al.
LEUKEMIA & LYMPHOMA (2008)
[18F] fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
Saar Gill et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma -: Relation to histologic subtypes-based on the World Health Organization Classification
Norifumi Tsukamoto et al.
CANCER (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
Malik E. Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas - Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
Christina Nickenig et al.
CANCER (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
MR Weihrauch et al.
BLOOD (2001)
(18)FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma
M de Wit et al.
ANNALS OF ONCOLOGY (2001)
Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients
JE Romaguera et al.
LEUKEMIA & LYMPHOMA (2000)
分享论文
